Dizal’s ZEGFROVY® Gets FDA Accelerated Approval for NSCLC Treatment
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the U.S. Food and...